Management of Measles in Adults
Measles management in adults is primarily supportive care with isolation, as there is no specific antiviral therapy; however, post-exposure prophylaxis with MMR vaccine (within 72 hours) or immune globulin (within 6 days) should be administered to susceptible exposed individuals, and vitamin A supplementation should be given to those at risk for severe disease.
Immediate Actions for Suspected Cases
When measles is suspected in an adult patient, implement airborne precautions immediately:
- Isolate the patient in an airborne infection isolation room (negative pressure)
- Require N-95 respirators for all healthcare personnel entering the room 1
- Remove exposed healthcare workers from patient contact for 5-21 days after exposure 2
Supportive Care (Primary Treatment)
Since no specific antiviral therapy exists for measles, management focuses on:
- Symptomatic treatment for fever, cough, and malaise
- Adequate hydration and nutrition
- Monitor for complications (occur in 10-40% of patients) 3
- Treat bacterial superinfections with appropriate antibiotics if they develop 3
Vitamin A Supplementation
Administer vitamin A to patients at high risk for severe disease, particularly those who are:
- Immunocompromised
- Malnourished
- Pregnant
- Hospitalized with complications 1
This is critical as measles causes transient immunodeficiency and vitamin A deficiency can lead to severe complications including blindness 4.
Post-Exposure Prophylaxis for Susceptible Contacts
For Immunocompetent Adults Without Evidence of Immunity:
MMR vaccine within 72 hours of exposure is the preferred intervention 2. This is most protective during this narrow window and will provide protection against subsequent exposures even if the current exposure results in infection.
Immune globulin (IG) within 6 days of exposure is the alternative when vaccine is contraindicated:
- Dose: 0.25 mL/kg IM (maximum 15 mL) for immunocompetent persons 2
- Note: If IG is given, defer MMR vaccine for 3 months to allow passive antibodies to clear 2
For Immunocompromised Adults and Pregnant Women:
Immune globulin is mandatory regardless of vaccination status:
- Immunocompromised patients: 0.5 mL/kg IM (maximum 15 mL) 5
- Pregnant women without immunity: Consider IGIV (intravenous immune globulin) as it may be more effective 6
- High-dose IGIV (100-400 mg/kg) may be as effective as IM IG 5
Evidence of Immunity Assessment
Before determining management, establish if the patient has evidence of immunity:
- Birth before 1957 (generally considered immune) 7
- Documentation of 2 doses of MMR vaccine
- Laboratory evidence of immunity (measles-specific IgG) 6
- Laboratory confirmation of previous disease 6
Important caveat: Provider-diagnosed disease without laboratory confirmation is no longer considered acceptable evidence of immunity per 2013 ACIP revisions 6.
Special Populations
Healthcare Workers
- Born before 1957: Still consider vaccination if no laboratory evidence of immunity 8
- Born 1957 or later: Require 2 doses of MMR for employment 8
- During outbreaks: Unvaccinated personnel should receive vaccine or be removed from patient contact 2
Pregnant Women
- Cannot receive MMR vaccine (live virus contraindicated) 2
- If exposed: Administer IGIV promptly 6
- If no evidence of immunity: Vaccinate immediately postpartum before hospital discharge 7
Immunocompromised Patients
- HIV-infected adults: Can receive MMR if CD4 counts indicate they do not have severe immunosuppression 6
- Those on high-dose corticosteroids (≥20 mg prednisone daily or ≥2 mg/kg for ≥14 days): Defer vaccination until 1 month after cessation 5
- Active leukemia: Wait 3 months after chemotherapy completion before vaccination 5
Laboratory Confirmation
Confirm suspected cases with:
- Measles-specific IgM antibody (most common test) 1
- Four-fold rise in IgG between acute and convalescent sera
- RT-PCR detection of measles virus RNA 3
- Viral culture (less commonly used)
Monitoring for Complications
Watch for serious complications that require aggressive management:
- Pneumonia (bacterial superinfection or viral)
- Encephalitis (high mortality risk) 4
- Secondary bacterial infections
- Complications are more common in immunocompromised patients, pregnant women, and those with vitamin A deficiency 1
Key Clinical Pitfall
Do not delay isolation while awaiting laboratory confirmation. The classic presentation of fever, cough, coryza, conjunctivitis, and maculopapular rash spreading cephalocaudally should trigger immediate airborne precautions 1, 3. Koplik spots (white enanthem on buccal mucosa) are pathognomonic when present 3, 4.